AtriCure Showcases Long-Term Growth Vision at Goldman Sachs 47th Annual Global Healthcare Conference 2026

AtriCure, Inc. (NASDAQ: ATRC), a leading medical technology company specializing in treatments for atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management, attracted significant attention during its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The event brought together healthcare executives, investors, analysts, and industry leaders to discuss the latest developments shaping the future of healthcare and medical technology.

The company's management team used the conference platform to provide investors with insights into AtriCure's business strategy, market opportunities, innovation pipeline, and long-term growth outlook. Executives emphasized the company's commitment to expanding its leadership position in cardiac surgery technologies while continuing to develop new solutions that address critical unmet patient needs.

Company Overview and Market Position

AtriCure has established itself as one of the leading innovators in the treatment of atrial fibrillation, one of the most common heart rhythm disorders worldwide. The company develops and commercializes advanced medical devices designed to improve patient outcomes through minimally invasive and surgical treatment options.

During the conference presentation, company representatives highlighted the growing prevalence of Afib globally. According to healthcare estimates, more than 59 million people worldwide are affected by atrial fibrillation, creating a substantial market opportunity for innovative treatment solutions.

The company's product portfolio includes several industry-leading technologies:

• Isolator® Synergy™ Ablation System
• AtriClip® Left Atrial Appendage Exclusion System
• Hybrid AF™ Therapy Solutions
• cryoICE® and cryoSPHERE® Pain Management Technologies

Management noted that these products continue to gain adoption among surgeons and healthcare providers worldwide due to their proven clinical effectiveness and strong safety profiles.

Strong Focus on Atrial Fibrillation Treatment

A major theme of the discussion centered around the company's continued leadership in atrial fibrillation treatment technologies. Atrial fibrillation remains one of the fastest-growing cardiovascular conditions globally, driven by aging populations and increasing prevalence of cardiovascular risk factors.

AtriCure executives explained that many patients remain undertreated despite significant advances in diagnosis and management. This treatment gap creates opportunities for innovative companies capable of delivering effective and durable solutions.

The company emphasized the importance of surgical ablation technologies in helping patients achieve long-term rhythm control. Its FDA-approved Isolator Synergy Ablation System remains a key growth driver and continues to differentiate AtriCure from competitors in the cardiac rhythm management market.

Growing Awareness Among Physicians

One of the factors supporting future growth is increasing physician awareness regarding the benefits of comprehensive Afib treatment strategies. More cardiac surgeons are incorporating advanced ablation procedures into routine clinical practice, resulting in broader utilization of AtriCure technologies.

Management indicated that ongoing educational initiatives and clinical evidence continue to strengthen physician confidence in the company's products.

Expansion of Left Atrial Appendage Management Business

Another key topic discussed during the conference was the rapid expansion of the company's left atrial appendage (LAA) management segment.

The AtriClip product family has become one of the most widely adopted solutions for LAA exclusion worldwide. Clinical studies have increasingly demonstrated the importance of managing the left atrial appendage in patients with atrial fibrillation to reduce stroke risk.

Executives highlighted several factors contributing to continued growth in this segment:

• Growing clinical evidence supporting LAA exclusion
• Increased physician adoption
• Expanding international markets
• Strong procedural volume growth
• Favorable reimbursement trends

Management believes the LAA market remains significantly underpenetrated, providing substantial room for future expansion.

Innovation Remains a Core Growth Driver

AtriCure reiterated that innovation remains at the center of its long-term business strategy. The company continues to invest heavily in research and development to expand its technology portfolio and address evolving physician needs.

Executives described how innovation has historically enabled AtriCure to maintain competitive advantages in highly specialized cardiovascular markets. By introducing new products and improving existing technologies, the company aims to strengthen customer relationships while driving sustainable revenue growth.

Research and development investments are expected to remain a priority as management pursues opportunities in both existing and adjacent markets.

Focus on Clinical Evidence

The company also stressed the importance of generating robust clinical evidence. Ongoing clinical studies continue to validate the effectiveness of AtriCure technologies and support broader adoption among healthcare providers.

Management believes that strong scientific evidence remains essential for driving physician confidence, improving reimbursement coverage, and expanding treatment guidelines.

Pain Management Portfolio Gains Momentum

In addition to cardiac rhythm management solutions, AtriCure continues to expand its presence in post-operative pain management.

The company's cryoICE and cryoSPHERE technologies are increasingly used to provide temporary nerve ablation for pain relief following surgical procedures. These products offer physicians valuable tools for reducing post-operative pain while minimizing reliance on opioid medications.

Conference attendees learned that demand for advanced pain management solutions continues to grow across multiple surgical specialties.

Management expressed optimism regarding future opportunities in this market segment, citing favorable healthcare trends and increasing emphasis on enhanced recovery protocols.

Financial Performance and Growth Outlook

During the fireside discussion, AtriCure executives addressed the company's financial performance and long-term outlook.

The leadership team highlighted several factors supporting sustained revenue growth:

• Expanding procedure volumes
• Growing physician adoption
• International market expansion
• Continued product innovation
• Increasing awareness of Afib treatment benefits

Management indicated confidence in the company's ability to capitalize on favorable industry trends while maintaining disciplined operational execution.

Investors responded positively to the company's emphasis on balanced growth, innovation, and long-term value creation.

International Market Opportunities

AtriCure also discussed its strategy for expanding internationally. While North America remains the company's largest market, management sees significant opportunities across Europe, Asia-Pacific, and other global regions.

Several international healthcare systems are increasing their focus on cardiovascular disease management, creating favorable conditions for adoption of advanced cardiac therapies.

The company continues to invest in commercial infrastructure, physician education programs, and market development initiatives to support international growth objectives.

Global Demand for Cardiac Care Solutions

Executives noted that the global burden of cardiovascular disease continues to rise. As healthcare systems seek more effective treatment options, demand for innovative technologies such as AtriCure's solutions is expected to increase.

This trend positions the company well for long-term international expansion.

Commitment to Patients and Healthcare Providers

A recurring message throughout the conference presentation was AtriCure's commitment to improving patient outcomes.

The company's mission extends beyond developing medical devices. Management emphasized the importance of collaborating with surgeons, hospitals, and healthcare systems to ensure patients receive optimal treatment solutions.

By focusing on clinical effectiveness, physician education, and patient-centered innovation, AtriCure aims to create lasting value across the healthcare ecosystem.

Investor Perspective

Investors attending the Goldman Sachs conference closely monitored discussions surrounding AtriCure's future growth potential.

Several aspects of the company's strategy attracted interest:

• Leadership in specialized cardiovascular markets
• Strong clinical evidence supporting products
• Large addressable market opportunities
• Diversified revenue streams
• Ongoing innovation initiatives

The company's ability to combine market leadership with continuous product innovation was viewed as an important competitive advantage.

Industry Trends Supporting Growth

The broader healthcare environment remains favorable for companies focused on cardiovascular innovation.

Key industry trends discussed during the conference included:

• Aging global populations
• Increasing prevalence of heart disease
• Greater emphasis on minimally invasive procedures
• Growing demand for evidence-based therapies
• Expansion of value-based healthcare models

AtriCure believes these trends will continue to support demand for its technologies over the coming years.

Future Strategic Priorities

Looking ahead, management outlined several strategic priorities designed to drive long-term success:

1. Expand adoption of existing product portfolio.
2. Advance clinical evidence generation.
3. Invest in research and development.
4. Increase international market penetration.
5. Strengthen physician education programs.
6. Enhance operational efficiency.
7. Pursue innovation opportunities in adjacent markets.

These initiatives are expected to support sustainable growth while reinforcing the company's position as a leader in cardiovascular medical technology.

Conclusion

AtriCure's participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 provided investors and industry stakeholders with a comprehensive overview of the company's growth strategy, innovation roadmap, and market opportunities.

Management highlighted strong momentum across its core businesses, including atrial fibrillation treatment, left atrial appendage management, and post-operative pain management. The company remains focused on expanding its clinical leadership, driving innovation, and improving patient outcomes worldwide.

With a growing global market, strong product portfolio, expanding clinical evidence, and commitment to innovation, AtriCure appears well-positioned to capitalize on emerging opportunities within the cardiovascular healthcare sector in the years ahead. Information regarding the company's conference participation and presentation schedule was publicly announced by AtriCure prior to the event.

#AtriCure #ATRC #HealthcareConference #MedicalTechnology #SlimScan #GrowthStocks #CANSLIM